Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 7/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20228785 | 0.90 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1TP53LMNA | |
| SCHEMBL18826078 | 0.85 | KMT2A (0.76) | ALDH1A1KMT2AMEN1TP53LMNA | |
| SCHEMBL13440499 | 0.82 | ALDH1A1 (0.74) | ALDH1A1KMT2AMEN1TP53LMNA | |
| SCHEMBL15722389 | 0.82 | KDM4E (0.73) | ALDH1A1KMT2AMEN1TP53POLB | |
| SCHEMBL12682848 | 0.81 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1TP53LMNA | |
| SCHEMBL15506196 | 0.78 | KDM4E (0.68) | ALDH1A1KMT2AMEN1TP53POLB | |
| SCHEMBL20228786 | 0.78 | KMT2A (1.00) | ALDH1A1KMT2AMEN1TP53POLB | |
| SCHEMBL19079755 | 0.77 | PDE4D (0.67) | ALDH1A1KMT2AMEN1TP53MAPT | |
| SCHEMBL20228788 | 0.77 | POLB (0.70) | ALDH1A1KMT2AMEN1TP53POLB | |
| SCHEMBL13407763 | 0.77 | KMT2A (1.00) | ALDH1A1KMT2AMEN1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370169-B2 | Small molecule Bcl-2 functional converters as cancer therapeutics | OREGON STATE UNIVERSITY (US) | 2025-07-29 | — | — | US | claimed |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-04-27 | — | — | US | claimed |
| US-20260014115-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2026-01-15 | — | — | US | disclosed |
| US-12370169-B2 | Small molecule Bcl-2 functional converters as cancer therapeutics | OREGON STATE UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-04-27 | — | — | US | disclosed |
| US-11419843-B2 | Small molecule BCL-2 functional converters as cancer therapeutics | OREGON STATE UNIVERSITY (US) | 2022-08-23 | — | — | US | disclosed |
| US-11419843-B2 | Small molecule BCL-2 functional converters as cancer therapeutics | OREGON STATE UNIVERSITY (US) | 2022-08-23 | — | — | US | disclosed |
| US-20190336469-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2019-11-07 | — | — | US | disclosed |
| WO-2018102766-A2 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014115-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | BCL2, BAX, BCL2A1 | ALDH1A1 3697/4885KMT2A 3281/4885MEN1 2030/4885 |
| US-12370169-B2 | Small molecule Bcl-2 functional converters as cancer therapeutics | BCL2, BCL2L1, BCL2L13 | ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885 |
| US-11419843-B2 | Small molecule BCL-2 functional converters as cancer therapeutics | BCL2, BCL2L1, BCL2L13 | ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885 |
| US-20190336469-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | BCL2, BCL2L1, BCL2L13 | ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885 |
| US-20230129487-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | BCL2, BCL2L1, BCL2L13 | ALDH1A1 3167/4885KMT2A 3078/4885MEN1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.